In the ELIXA CVOT, lixisenatide was found to be non-inferior to standard of care plus placebo in terms of risk of the composite endpoint (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina)13.4% in the lixisenatide group and 13.2% in the placebo group (hazard ratio, 1.02
What is Dragon Pharma BPC 157
You can log each dose as you take it, which gives you a clear record of where you are in your titration schedule
She is suing the makers of both drugs, Novo Nordisk and Eli Lilly, for failing to warn of the risk of severe gastrointestinal events that could be caused by taking the medications
Unfortunately, sperm are particularly vulnerable to the damages of oxidative stress
Weight cycling or yo-yo-ing has a negative effect on metabolism, and is really hard on body image and self-esteem